China Pharma Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
China Pharma Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue4.537.018.109.6410.87
Cost of Revenue6.517.298.609.298.91
Gross Profit-1.99-0.28-0.490.351.95
Operating Expenses
Research & Development0.280.240.190.320.38
Selling, General & Administrative2.312.252.963.154.04
Operating Expenses2.602.493.063.214.53
Operating Income-4.59-2.77-3.55-2.86-2.58
Other Income/Expense
Interest Income0.010.010.010.000.01
Interest Expense0.150.33-0.43-0.54-0.29
Other Income/Expense-0.150.020.090.260.00
Income
Income Before Tax-4.74-3.08-3.97-3.40-2.87
Income Tax Expense0.000.000.010.000.01
Net Income-4.74-3.08-3.97-3.40-2.87
Net Income - Continuous Operations-4.74-3.08-3.97-3.400.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-1.960.01-0.850.230.10
EBIT-4.58-2.75-3.55-2.86-2.58
Depreciation & Amortization2.622.752.703.092.68
Earnings Per Share
Basic EPS--9.00-38.00-37.00-33.00
Diluted EPS--9.00-38.00-37.00-33.00
Basic Shares Outstanding17.460.340.110.090.09
Diluted Shares Outstanding17.460.340.110.090.09